Bladder Cancer Clinical Trial
Official title:
Diode Laser Treatment of Pta Low Grade Bladder Tumors in the Outpatient Department.
Laser treatment of pTa low grade bladder tumours in the outpatient department
Number of Subjects/Centres Planned: 20 patients will be included in this study. The study
will be performed at Department of Urology, Bispebjerg-Frederiksberg Hospital, Copenhagen,
Denmark.
Primary Objective: To show that small pTa bladder tumours safely can be removed with diode
laser in an outpatient department Secondary Objective: To evaluate the patients experience
with the laser treatment using QOL questionaires (symptom evaluation) and Visual Analog
Scale Score (pain evaluation).
Laser treatment of pTa low grade bladder tumours in the outpatient department
Number of Subjects/Centres Planned: 20 patients will be included in this study. The study
will be performed at Department of Urology, Bispebjerg-Frederiksberg Hospital, Copenhagen,
Denmark.
Primary Objective: To show that small pTa bladder tumours safely can be removed with diode
laser in an outpatient department Secondary Objective: To evaluate the patients experience
with the laser treatment using QOL questionaires (symptom evaluation) and Visual Analog
Scale Score (pain evaluation).
Study Design: Open prospective study in patients with recurrent pTa low grade bladder
tumours.
All patients will have their bladder tumour removed using a diode laser. The treatment will
take place in the outpatient department (OPD) without any pain treatment. Biopsy from the
tumour will be obtained before the procedure. If the biopsy shows low grade non-invasive
bladder tumour, flexible cystoscopy will be repeated one month later in the OPD. At both
procedures biopsy will be taken from the laser treated area.
If the per-operative biopsy shows high grade or invasive tumour, the patient will be
referred for a re-resection at the operating theatre during admittance to the urology ward.
The pain is valuated by a Visual Analogue Scale Score and filled out immediately after each
procedure.
Treatment induced symptoms will be evaluated using a QOL questionnaire which the patient
fills out one week after the laser treatment and one week after the cystoscopies.
Population: Patients with histologically confirmed pTa urothelial bladder tumours Number of
Subjects: Twenty patients Selection of Subjects: Patients scheduled for a trans urethral
resection of bladder tumour (TUR-B) less than 1,5 cm at the operating theatre under general
anaesthesia and without concomitant therapy with anticoagulants as Marevan, Marcoumar, and
the new anticoagulants as Pradaxa etc. will after informed consent be included in the study.
Equipment:
Diode laser Storz, SPIES Biopsy forceps, Storz
Key Dates:
Overall duration of the study: 6 months included 1 months follow up Efficacy and Safety
Variables Primary Endpoint: proportion of patients where the bladder tumours are completely
removed by one laser treatment.
Secondary Endpoints:
- Portion of general urinary problems and QOL after laser treatment compared to
cystoscopy and biopsy in the OPD
- Pain at the laser treatment and the cystoscopy assessed by Visual Analog Scale (VAS)
Score.
Statistical Methods and Planned Analysis: Non-parametric and descriptive statistics will be
performed
Parameters in the case report form (CRF):
Bladder cancer diagnosis (pTa low grade)
- Age
- Sex
- Mapping of lesions in normal, Clara Chrome, Spectra A and B filter cystoscopy
- Histology of all suspicious lesions
- SEPARATE CYSTOSCOPYFORM for laser TUR-B and the two follow up cystoscopies
- The duration of the laser treatment
- Expected clearance after the laser TUR-B
- The visibility during the laser TUR-B
- Visual Analog Scale Score result (to measure pain when laser treatment is performed and
biopsies are taken in the OPD)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |